A Phase 3 interventional study of SAR153191 (REGN88) in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 335 sites in 40 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one has the largest enrollment, is one of 4 that started in 2010, is one of 9 in phase 3, and was the 5th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,023 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one has the largest enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2010, is one of 9 in phase 3, and was the 10th registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Main Study:
Primary Objective:
Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA).
Secondary Objective:
Assess the long term efficacy of sarilumab in participants with RA.
Sub-Study:
This phase 3, open label sub-study was aimed to assess the usability of PFS-S when used by participants with moderate or severe RA, or their professional or non-professional healthcare providers in an unsupervised real-world situation. To mimic the real-world practice, the sub-study was incorporated into the LTS11210 study without additional visits compared to the scheduled visits in the main study. The duration of this sub-study was 12 weeks.
The maximum duration of the study was up to 523 weeks:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Main study:
Participants with RA who were previously randomized in the sarilumab RA clinical program: e.g., the EFC11072 study, ACT11575 study, EFC10832 study, SFY13370, and EFC13752 study.
Sub-study:
Participants enrolled in the LTS11210 study who were receiving either sarilumab 200mg q2w PFS or sarilumab 150mg q2w PFS and who were able and willing to participate in this sub-study.
Participants who had been enrolled in the main study for at least 24 weeks. Participants must sign a sub-study written prior to any sub-study related procedure.
Exclusion criteria:
Main study:
Participants with any adverse event (AE) led to permanent study drug discontinuation from a prior study.
Participants with an abnormality(ies) or AEs that per investigator judgment would adversely affect participation of the participant in the study.
Sub-study: There are no additional exclusion criteria to those defined in main study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who completed any of initial studies:Part A or B of EFC11072, ACT11575, EFC10832 or SFY13370 were enrolled in LTS11210 and received sarilumab 150 milligrams (mg) subcutaneously (SC) once weekly (qw). Dose could be reduced to 150 mg every 2 weeks (q2w) due to neutropenia, thrombocytopenia or increase in liver enzymes (alanine aminotransferase \[ALT\]). After dose regimens selection for Phase 3 studies (150 mg q2w and 200 mg q2w), participants already receiving 150 mg qw were switched to sarilumab 200 mg q2w. Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks). Participants who were already taking concomitant non-biologic DMARDs in initial study continued stable dose of one or combination of conventional synthetic DMARDs they were taking.
Drug: SAR153191 (REGN88)
Participants who completed study EFC13752 were enrolled in LTS11210 and received sarilumab 200 mg q2w. Dose could be reduced to 150 mg q2w due to neutropenia, thrombocytopenia or increase in liver enzymes (ALT). Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks).
Drug: SAR153191 (REGN88)
Pharmaceutical form: solution Route of administration: subcutaneous
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product and which did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) in study LTS11210 to the last dose of the IMP +60 days).
Time frame: From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)
Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System
A PTF was defined as any product technical complaint (PTC) related to the use of the PFS-S that had a validated technical cause. FDD was defined as participant's failure to administer the full dose at a given attempt. A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Participants who answered "no" for any of the questions of PTC, had PTF and/or FDD were reported in this outcome measure.
Time frame: From Week 24 to 36
Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System
A PTF was defined as any PTC (defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary) related to the use of the PFS-S that had a validated technical cause. Number of PTF in the participants enrolled in sub-study were reported in this outcome measure.
Time frame: From Week 24 to 36
Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System
FDD was defined as participant's failure to administer the full dose at a given attempt. Number of FDD in the participants enrolled in sub-study were reported in this outcome measure.
Time frame: From Week 24 to 36
Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System
A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Number of PTC (based on participant's answer to "no" for any of the questions of PTC) in the participants enrolled in sub-study were reported in this outcome measure.
Time frame: From Week 24 to 36
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response
ACR20 response: greater than or equal to (\>=) 20% improvement in both tender joint count and swollen joint count and, \>=20% improvement in at least 3 of the 5 remaining ACR core measures assessments: C-reactive protein \[CRP\] level (mg/liter \[mg/L\]); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.
Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response
ACR50 response: \>=50% improvement in both TJC and SJC, and \>=50% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.
Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response
ACR70 response: \>=70% improvement in both TJC and SJC, and \>=70% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.
Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Percentage of Participants With Disease Activity Score for 28 Joints (DAS28) Remission
Disease activity score based on 28 joints and C-reactive protein (DAS28-CRP) was a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0 to 10, where higher scores indicated greater disease activity. Percentage of participants with DAS28 remission were reported.
Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Percentage of Participants Achieving Good Response, Moderate Response or Non-response Using the European League Against Rheumatism (EULAR) Response Criteria
DAS28-based EULAR response criteria were used to measure individual response as none, good or moderate, depending on the extent of change from baseline and level of disease activity reached. The EULAR response criteria are defined as: * Good response = change from baseline of \>1.2 and a present DAS28-CRP score \<=3.2. * Moderate response = change from baseline of \>0.6 to \<=1.2 and a present DAS28-CRP score \<=5.1, or, change from baseline of \>1.2 and present DAS28-CRP score \>3.2. * Non-response = change from baseline of \<=0.6, or change from baseline of \>0.6 to \<=1.2 and present DAS28-CRP score \>5.1. Scores of good and moderate were considered to indicate therapeutic response. DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS.
Time frame: At Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Change From Baseline in DAS28-CRP Score at Weeks 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0-10, where higher scores indicated greater disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
HAQ-DI is a standardized questionnaire used to assess the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; hygiene; reach; grip and activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3, where 0= no difficulty in physical function; 1= some difficulty in physical function; 2= much difficulty in physical function; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty in physical function) to 3 (extreme difficulty in physical function), where higher scores indicate more difficulty while performing daily living activities. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 0 and Week 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B
Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both joint erosions (JE) for 44 joints and joint space narrowing (JSN) for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study Baseline in 2 years X-ray data at Week 0 and 48 of LTS11210 were reported.
Time frame: Baseline, Week 0 and 48 of LTS11210
Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B
Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 3 years X-ray data (participants with study duration of more than 48 weeks in LTS11210) at Week 48 and 96 of LTS11210 from Campaign 2 were reported.
Time frame: Baseline, Week 48 and 96 of LTS11210
Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 96, Week 144 and Week 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B
Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 5 years X-ray data (participants with study duration of more than 96 weeks in LTS11210) at Week 96, 144 and 192 of LTS11210 from Campaign 3 were reported.
Time frame: Baseline, Week 96, 144 and 192 of LTS11210
Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 0 and 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B
Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 of LTS11210 from Campaign 1 X-ray data were reported.
Time frame: Week 0 (post-dose) and 48 of LTS11210
Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B
Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 and 96 of LTS11210 from Campaign 2 X-ray data (participants with study duration of more than 48 weeks in LTS11210) were reported.
Time frame: Week 48 and 96 of LTS11210
Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 96, 144 and 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B
Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 96, 144 and 192 of LTS11210 from Campaign 3 X-ray data (participants with study duration more than 96 weeks in LTS11210) were reported.
Time frame: Week 96, 144 and 192 of LTS11210
Change From Baseline in Tender Joint Count (TJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
TJC is the sum of all tender joints based on examination of the 68 joints of the fingers, elbows, hips, knees, ankles, and toes. Total TJC ranged from 0 (best) to 68 (worst), where higher score = more severity. Change from Baseline in TJC was reported in the outcome measure. Here, Baseline refers to Baseline of initial study (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Change From Baseline in Swollen Joint Count (SJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
SJC is the sum of all swollen joints based on examination of the fingers, elbows, knees and toes. Total SJC ranged from 0 (best) to 66 (worst), where higher score = more severity. Change from Baseline in SJC was reported in the outcome measure. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Change From Baseline in Physician's Global Assessments of Disease Activity Visual Analogue Scale (VAS) Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
Physician global assessment of disease activity was measured on a 100 millimeters (mm) horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
Change From Baseline in Participant Global Assessment of Disease Activity Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Participant global assessment of disease activity was measured on a 100 mm horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210
Change From Baseline in Participant's Assessment of Pain Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
Participants were requested to indicate their pain intensity due to their RA on a 100 mm horizontal VAS, ranging from 0 (no pain) to 100 (worst pain), where a higher score represented more pain due to RA. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
Time frame: Baseline, Week 0 (post-dose), 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210
Change From Baseline in Short Form 36 (SF-36; Version 2) Physical Component Summary (PCS) Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only
SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; where 0= worst QoL to 100=best QoL. PCS total score ranged from 0 to 100 with higher scores indicating better physical health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).
Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Short Form 36 (SF-36; Version 2) Mental Component Summary Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only
SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and MCS. PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; 0= worst QoL to 100=best QoL. MCS total score ranged from 0 to 100 with higher scores indicating better physical and mental health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).
Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Total Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210-Participants From EFC11072, ACT11575 and EFC10832 Only
The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. The sum of all responses resulted in the FACIT-Fatigue total score ranged from 0 to 52, where higher score = lower level of fatigue and indicates better QoL. A positive change from baseline score indicates an improvement. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).
Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Sleep Visual Analogue Scale Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
Rheumatoid arthritis (RA), like other chronic illness, is associated with sleep disturbances and is linked to pain, mood, and disease activity. The effect of sarilumab on sleep was assessed on a on 100 mm horizontal VAS scale, ranging from 0 (sleep is not a problem) to 100 (sleep is a major problem), where higher score = more sleep disturbances. Here, Baseline refers to the Baseline of initial studies (EFC11072, and ACT11575).
Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to RA at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072 and ACT11575 Only
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers indicated greater impairment). The percent work time missed due to RA was a subscale and calculated as: 100\*Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as impairment percentage (range:0 to 100%) where higher numbers indicate greater impairment and less productivity. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).
Time frame: Baseline, Week 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Work Productivity and Activity Impairment: Percent Impairment While Working Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers = less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers = greater impairment). Percentage impairment while working due to RA was subscale and calculated as: 10\*Q5 for those who were currently employed and actually worked in past 7 days. Subscale score=expressed as impairment percentage (range:0 to 100%), where higher numbers=greater impairment and less productivity. Here, Baseline refers to the Baseline of initial studies (EFC11072 and ACT11575).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Work Productivity and Activity Impairment: Percent Overall Work Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent overall work impairment due to RA was subscale and calculated as: 100\*Q2/(Q2+Q4)+100\*\[(1- Q2/(Q2+Q4))\*(Q5/10)\] for those who were currently employed . Subscale score = expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Work Productivity and Activity Impairment: Percent Activity Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent activity impairment due to RA was a subscale and calculated as: 10\*Q6 for all respondents. Subscale score=expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Work Days Missed Due to Arthritis - Participants From EFC10832 Only
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with arthritis over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days missed in the last month due to arthritis by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days with reduced productivity by \>= 50% in the last month by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Work Productivity - Participants From EFC10832 Only
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: House Work Days Missed Due to Arthritis - Participants From EFC10832 Only
'The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with no household work/household work missed in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Household Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Family/Social/Leisure Activities Missed Due to Arthritis - Participants From EFC10832 Only
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days missed of family/social/leisure activities in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Outside Help Hired Due to Arthritis- Participants From EFC10832 Only
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with outside help hired in the last month by the participant was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Household Work Productivity - Participants From EFC10832 Only
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).
Time frame: Baseline, Weeks 0 (post-dose), 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210
Sub-study: Number of Participants Who Reported Adverse Events Related to Pre-filled Syringe With Safety System
AEs related to PFS-S included PTC-related AEs, device-related AEs, or AEs of injection site reaction. In this outcome measure, only PTC-related AEs, device-related AEs, or AEs of injection site reaction assessed during the sub-study were reported. TEAEs and SAEs reported during the sub-study were included in the main study data and no separate data collection and analysis was performed, as pre-planned in the protocol .
Time frame: From Week 24 to 36
Participants who completed any of studies EFC11072 (NCT01061736), ACT11575 ( NCT01217814), EFC10832 (NCT01709578), SFY13370 (NCT01768572), EFC13752 (NCT02121210) were eligible for enrollment in LTS11210 (named as main study). A total of 2023 participants were enrolled between 21 June 2010 and 04 May 2015. From Week 24 of LTS11210, willing participants were enrolled in a 12-week sub-study (part of main study only) to assess usability of pre-filled syringe with safety system (PFS-S).
| Milestone | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Started | 1912 | 111 |
| Treated | 1910 | 111 |
| Enrolled in the sub-study | 110 | 14 |
| Discontinued from the sub-study | 1 | 2 |
| Switched back to main study | 108 | 13 |
| Completed | 961 | 66 |
| Not completed | 951 | 45 |
| Withdrew: Adverse event | 506 | 15 |
| Withdrew: Lack of efficacy | 91 | 7 |
| Withdrew: Poor compliance to protocol | 38 | 1 |
| Withdrew: Other unspecified reasons | 314 | 22 |
| Withdrew: Enrolled but not treated | 2 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product and which did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product (IMP) in study LTS11210 to the last dose of the IMP +60 days).
| Participants | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Any TEAE | 1760 | 98 |
| Any TE SAE | 617 | 27 |
A PTF was defined as any product technical complaint (PTC) related to the use of the PFS-S that had a validated technical cause. FDD was defined as participant's failure to administer the full dose at a given attempt. A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Participants who answered "no" for any of the questions of PTC, had PTF and/or FDD were reported in this outcome measure.
| Participants | PFS-S Sarilumab 150 mg q2w | PFS-S Sarilumab 200 mg q2w | PFS-S Sarilumab 200 to 150 mg q2w |
|---|---|---|---|
| PFS-S-associated PTF | 0 | 0 | 0 |
| PFS-S-associated FDD | 0 | 5 | 0 |
| PFS-S-associated PTC | 0 | 5 | 0 |
A PTF was defined as any PTC (defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary) related to the use of the PFS-S that had a validated technical cause. Number of PTF in the participants enrolled in sub-study were reported in this outcome measure.
| PTF | PFS-S Sarilumab 150 mg q2w | PFS-S Sarilumab 200 mg q2w | PFS-S Sarilumab 200 to 150 mg q2w |
|---|---|---|---|
| Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System | 0 | 0 | 0 |
FDD was defined as participant's failure to administer the full dose at a given attempt. Number of FDD in the participants enrolled in sub-study were reported in this outcome measure.
| FDD | PFS-S Sarilumab 150 mg q2w | PFS-S Sarilumab 200 mg q2w | PFS-S Sarilumab 200 to 150 mg q2w |
|---|---|---|---|
| Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System | 0 | 5 | 0 |
A PTC was defined as any participant- or healthcare provider-reported complaint regarding the use of the PFS-S syringe and collected via the completion of the injection diary. The injection diary comprised specific questions: 1. Were you able to remove the cap? 2. Was the needle safety system activated?, 3. Did the safety system entirely cover the needle, and 4. Was the person who performed the injection the person who was trained by the site staff?, where each question was given the option yes/no. Number of PTC (based on participant's answer to "no" for any of the questions of PTC) in the participants enrolled in sub-study were reported in this outcome measure.
| PTC | PFS-S Sarilumab 150 mg q2w | PFS-S Sarilumab 200 mg q2w | PFS-S Sarilumab 200 to 150 mg q2w |
|---|---|---|---|
| Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System | 0 | 5 | 0 |
ACR20 response: greater than or equal to (\>=) 20% improvement in both tender joint count and swollen joint count and, \>=20% improvement in at least 3 of the 5 remaining ACR core measures assessments: C-reactive protein \[CRP\] level (mg/liter \[mg/L\]); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] visual analog scale \[VAS\]); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by health assessment questionnaire disability index \[HAQ-DI\], with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.
| percentage of participants | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | 69.4 (67.3 to 71.5) | 82.0 (73.6 to 88.6) |
| Week 4 | 77.8 (75.8 to 79.6) | 85.8 (77.7 to 91.9) |
| Week 8 | 80.2 (78.3 to 82.0) | 92.5 (85.7 to 96.7) |
| Week 12 | 80.3 (78.4 to 82.1) | 91.7 (84.9 to 96.2) |
| Week 24 | 82.9 (81.1 to 84.6) | 88.1 (80.5 to 93.5) |
| Week 36 | 82.8 (80.9 to 84.5) | 91.7 (84.9 to 96.2) |
| Week 48 | 82.9 (81.0 to 84.7) | 85.0 (76.9 to 91.2) |
| Week 60 | 84.6 (82.8 to 86.3) | 93.2 (86.5 to 97.2) |
| Week 72 | 84.4 (82.5 to 86.1) | 94.1 (87.5 to 97.8) |
| Week 84 | 84.5 (82.6 to 86.2) | 94.7 (88.1 to 98.3) |
| Week 96 | 85.2 (83.3 to 87.0) | 91.3 (83.6 to 96.2) |
| Week 120 | 84.9 (82.9 to 86.7) | 90.9 (82.9 to 96.0) |
| Week 144 | 86.4 (84.5 to 88.2) | 94.0 (86.5 to 98.0) |
| Week 168 | 86.0 (84.0 to 87.8) | 90.1 (81.5 to 95.6) |
| Week 192 | 85.7 (83.7 to 87.6) | 89.3 (80.1 to 95.3) |
| Week 216 | 87.1 (85.1 to 89.0) | 89.2 (79.8 to 95.2) |
| Week 240 | 86.4 (84.3 to 88.4) | 91.9 (83.2 to 97.0) |
| Week 264 | 88.5 (86.4 to 90.3) | 90.2 (79.8 to 96.3) |
ACR50 response: \>=50% improvement in both TJC and SJC, and \>=50% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.
| percentage of participants | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | 43.4 (41.2 to 45.7) | 58.6 (48.8 to 67.8) |
| Week 4 | 51.3 (49.0 to 53.6) | 59.3 (49.4 to 68.6) |
| Week 8 | 55.1 (52.8 to 57.4) | 59.0 (49.0 to 68.5) |
| Week 12 | 58.1 (55.8 to 60.4) | 66.7 (56.9 to 75.4) |
| Week 24 | 60.5 (58.2 to 62.8) | 64.2 (54.5 to 73.2) |
| Week 36 | 62.1 (59.8 to 64.4) | 64.2 (54.5 to 73.2) |
| Week 48 | 62.4 (60.0 to 64.7) | 69.2 (59.5 to 77.7) |
| Week 60 | 63.2 (60.8 to 65.6) | 68.9 (59.1 to 77.7) |
| Week 72 | 64.8 (62.4 to 67.1) | 71.3 (61.4 to 79.9) |
| Week 84 | 63.6 (61.2 to 66.1) | 73.4 (63.3 to 82.0) |
| Week 96 | 65.3 (62.8 to 67.7) | 71.7 (61.4 to 80.6) |
| Week 120 | 65.6 (63.1 to 68.0) | 73.6 (63.0 to 82.4) |
| Week 144 | 65.7 (63.1 to 68.2) | 70.2 (59.3 to 79.7) |
| Week 168 | 66.2 (63.6 to 68.8) | 70.0 (58.7 to 79.7) |
| Week 192 | 68.4 (65.8 to 71.0) | 70.7 (59.0 to 80.6) |
| Week 216 | 69.0 (66.3 to 71.7) | 75.7 (64.3 to 84.9) |
| Week 240 | 68.3 (65.5 to 71.0) | 79.7 (68.8 to 88.2) |
| Week 264 | 69.6 (66.7 to 72.4) | 71.7 (58.6 to 82.5) |
ACR70 response: \>=70% improvement in both TJC and SJC, and \>=70% improvement in at least 3 of the 5 remaining ACR core measures assessments: CRP level (in mg/L); participant's assessment of pain (measured on 0 \[no pain\] to 100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]to 100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] to 3 \[worst physical function\]). Higher score indicated worse outcomes.
| percentage of participants | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | 22.9 (21.0 to 24.8) | 32.4 (23.9 to 42.0) |
| Week 4 | 27.8 (25.8 to 29.9) | 31.5 (22.9 to 41.1) |
| Week 8 | 32.1 (30.0 to 34.3) | 36.2 (27.0 to 46.1) |
| Week 12 | 34.1 (31.9 to 36.3) | 43.0 (33.5 to 52.9) |
| Week 24 | 38.7 (36.4 to 41.0) | 37.4 (28.2 to 47.3) |
| Week 36 | 40.2 (37.9 to 42.6) | 40.4 (31.1 to 50.2) |
| Week 48 | 40.6 (38.3 to 43.0) | 43.8 (34.1 to 53.8) |
| Week 60 | 41.6 (39.2 to 44.0) | 45.6 (35.8 to 55.7) |
| Week 72 | 42.1 (39.6 to 44.6) | 49.0 (38.9 to 59.2) |
| Week 84 | 41.8 (39.3 to 44.3) | 52.1 (41.6 to 62.5) |
| Week 96 | 43.4 (40.9 to 45.9) | 55.4 (44.7 to 65.8) |
| Week 120 | 42.9 (40.3 to 45.5) | 56.8 (45.8 to 67.3) |
| Week 144 | 44.7 (42.0 to 47.3) | 50.0 (38.9 to 61.1) |
| Week 168 | 45.6 (42.9 to 48.4) | 51.3 (39.8 to 62.6) |
| Week 192 | 47.9 (45.1 to 50.7) | 53.9 (42.1 to 65.5) |
| Week 216 | 46.8 (43.9 to 49.7) | 62.0 (49.7 to 73.2) |
| Week 240 | 47.9 (44.9 to 50.9) | 60.8 (48.8 to 72.0) |
| Week 264 | 48.8 (45.7 to 51.9) | 58.3 (44.9 to 70.9) |
Disease activity score based on 28 joints and C-reactive protein (DAS28-CRP) was a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0 to 10, where higher scores indicated greater disease activity. Percentage of participants with DAS28 remission were reported.
| percentage of participants | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | 30.4 (28.3 to 32.5) | 46.4 (36.8 to 56.1) |
| Week 4 | 39.2 (36.9 to 41.4) | 51.9 (42.0 to 61.7) |
| Week 8 | 44.6 (42.3 to 46.9) | 49.5 (39.6 to 59.5) |
| Week 12 | 47.9 (45.6 to 50.3) | 55.0 (45.2 to 64.6) |
| Week 24 | 50.6 (48.2 to 52.9) | 59.6 (49.8 to 68.9) |
| Week 36 | 51.7 (49.3 to 54.1) | 59.6 (49.8 to 68.9) |
| Week 48 | 53.7 (51.3 to 56.1) | 56.1 (46.1 to 65.7) |
| Week 60 | 56.5 (54.1 to 59.0) | 61.8 (51.6 to 71.2) |
| Week 72 | 55.8 (53.3 to 58.3) | 68.3 (58.3 to 77.2) |
| Week 84 | 55.8 (53.2 to 58.3) | 70.5 (60.3 to 79.4) |
| Week 96 | 57.0 (54.5 to 59.6) | 71.7 (61.4 to 80.6) |
| Week 120 | 59.2 (56.6 to 61.8) | 73.9 (63.4 to 82.7) |
| Week 144 | 59.3 (56.7 to 61.9) | 72.3 (61.4 to 81.6) |
| Week 168 | 59.7 (56.9 to 62.3) | 70.4 (59.2 to 80.0) |
| Week 192 | 62.1 (59.3 to 64.8) | 67.1 (55.4 to 77.5) |
| Week 216 | 63.6 (60.7 to 66.3) | 71.2 (59.4 to 81.2) |
| Week 240 | 61.6 (58.7 to 64.5) | 82.2 (71.5 to 90.2) |
| Week 264 | 64.4 (61.4 to 67.3) | 75.8 (63.3 to 85.8) |
| Week 288 | 68.7 (65.1 to 72.1) | 73.1 (52.2 to 88.4) |
| Week 312 | 69.0 (65.3 to 72.5) | 85.7 (42.1 to 99.6) |
| Week 336 | 72.2 (68.2 to 76.0) | — |
| Week 360 | 71.7 (67.2 to 75.9) | — |
| Week 384 | 71.6 (66.4 to 76.3) | — |
| Week 408 | 69.8 (63.0 to 76.1) | — |
| Week 432 | 76.4 (67.2 to 84.1) | — |
| Week 456 | 72.7 (59.0 to 83.9) | — |
| Week 480 | 76.9 (60.7 to 88.9) | — |
| Week 504 | 73.1 (52.2 to 88.4) | — |
| Week 516 | 50.0 (1.3 to 98.7) | — |
DAS28-based EULAR response criteria were used to measure individual response as none, good or moderate, depending on the extent of change from baseline and level of disease activity reached. The EULAR response criteria are defined as: * Good response = change from baseline of \>1.2 and a present DAS28-CRP score \<=3.2. * Moderate response = change from baseline of \>0.6 to \<=1.2 and a present DAS28-CRP score \<=5.1, or, change from baseline of \>1.2 and present DAS28-CRP score \>3.2. * Non-response = change from baseline of \<=0.6, or change from baseline of \>0.6 to \<=1.2 and present DAS28-CRP score \>5.1. Scores of good and moderate were considered to indicate therapeutic response. DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS.
| percentage of participants | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0: Good response | 44.7 | 60.9 |
| Week 0: Moderate response | 40.3 | 30.9 |
| Week 0: None response | 15.0 | 8.2 |
| Week 4: Good response | 57.2 | 69.8 |
| Week 4: Moderate response | 36.2 | 26.4 |
| Week 4:None response | 6.6 | 3.8 |
| Week 8: Good response | 62.3 | 68.6 |
| Week 8: Moderate response | 31.7 | 27.6 |
| Week 8: None response | 6.0 | 3.8 |
| Week 12: Good response | 64.1 | 74.3 |
| Week 12: Moderate response | 30.6 | 22.9 |
| Week 12: None response | 5.2 | 2.8 |
| Week 24: Good response | 66.6 | 73.4 |
| Week 24: Moderate response | 28.9 | 24.8 |
| Week 24: None response | 4.5 | 1.8 |
| Week 36: Good response | 67.9 | 71.6 |
| Week 36: Moderate response | 27.0 | 24.8 |
| Week 36: None response | 5.1 | 3.7 |
| Week 48: Good response | 68.1 | 72.0 |
| Week 48: Moderate response | 27.4 | 24.3 |
| Week 48: None response | 4.5 | 3.7 |
| Week 60: Good response | 71.1 | 68.6 |
| Week 60: Moderate response | 24.6 | 29.4 |
| Week 60: None response | 4.2 | 2.0 |
| Week 72: Good response | 70.0 | 81.2 |
| Week 72: Moderate response | 26.0 | 16.8 |
| Week 72: None response | 4.0 | 2.0 |
| Week 84: Good response | 71.3 | 84.2 |
| Week 84: Moderate response | 24.2 | 14.7 |
| Week 84: None response | 4.6 | 1.1 |
| Week 96: Good response | 72.6 | 76.1 |
| Week 96: Moderate response | 23.3 | 21.7 |
| Week 96: None response | 4.1 | 2.2 |
| Week 120: Good response | 73.5 | 80.7 |
| Week 120: Moderate response | 22.3 | 17.0 |
| Week 120: None response | 4.2 | 2.3 |
| Week 144: Good response | 73.3 | 86.7 |
| Week 144: Moderate response | 22.8 | 13.3 |
| Week 144: None response | 3.9 | 0 |
| Week 168: Good response | 74.5 | 84.0 |
| Week 168: Moderate response | 20.6 | 16.0 |
| Week 168: None response | 4.9 | 0 |
| Week 192: Good response | 75.6 | 81.6 |
| Week 192: Moderate response | 20.6 | 13.2 |
| Week 192: None response | 3.8 | 5.3 |
| Week 216: Good response | 75.9 | 80.8 |
| Week 216: Moderate response | 20.5 | 17.8 |
| Week 216: None response | 3.6 | 1.4 |
| Week 240: Good response | 78.6 | 89.0 |
| Week 240: Moderate response | 17.5 | 9.6 |
| Week 240: None response | 3.8 | 1.4 |
| Week 264: Good response | 76.7 | 83.9 |
| Week 264: Moderate response | 20.2 | 16.1 |
| Week 264: None response | 3.1 | 0 |
| Week 288: Good response | 82.4 | 80.8 |
| Week 288: Moderate response | 15.2 | 19.2 |
| Week 288: None response | 2.4 | 0 |
| Week 312: Good response | 81.5 | 100 |
| Week 312: Moderate response | 16.3 | 0 |
| Week 312: None response | 2.1 | 0 |
| Week 336: Good response | 83.0 | — |
| Week 336: Moderate response | 14.6 | — |
| Week 336: None response | 2.4 | — |
| Week 360: Good response | 83.3 | — |
| Week 360: Moderate response | 15.1 | — |
| Week 360: None response | 1.7 | — |
| Week 384: Good response | 86.2 | — |
| Week 384: Moderate response | 12.9 | — |
| Week 384: None response | 0.9 | — |
| Week 408: Good response | 81.9 | — |
| Week 408: Moderate response | 16.1 | — |
| Week 408: None response | 2.0 | — |
| Week 432: Good response | 85.8 | — |
| Week 432: Moderate response | 14.2 | — |
| Week 432: None response | 0 | — |
| Week 456: Good response | 87.3 | — |
| Week 456: Moderate response | 12.7 | — |
| Week 456: None response | 0 | — |
| Week 480: Good response | 79.5 | — |
| Week 480: Moderate response | 17.9 | — |
| Week 480: None response | 2.6 | — |
| Week 504: Good response | 92.3 | — |
| Week 504: Moderate response | 7.7 | — |
| Week 504: None response | 0 | — |
| Week 516: Good response | 100 | — |
| Week 516: Moderate response | 0 | — |
| Week 516: None response | 0 | — |
DAS28-CRP is a composite score which included 4 components: TJC with 28 joints assessed; SJC with 28 joints assessed; high-sensitivity CRP (in mg/L) and general health assessment by the participant using participant global assessment (measured on 0 \[no arthritis activity\] to 100 mm \[maximal arthritis activity\] VAS). DAS28-CRP total score ranges from 0-10, where higher scores indicated greater disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
| units on a scale | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | -2.50 ± 1.52 | -2.99 ± 1.42 |
| Week 4 | -2.98 ± 1.38 | -3.18 ± 1.31 |
| Week 8 | -3.12 ± 1.41 | -3.21 ± 1.26 |
| Week 12 | -3.19 ± 1.41 | -3.28 ± 1.29 |
| Week 24 | -3.28 ± 1.41 | -3.43 ± 1.21 |
| Week 36 | -3.31 ± 1.43 | -3.35 ± 1.23 |
| Week 48 | -3.35 ± 1.42 | -3.36 ± 1.35 |
| Week 60 | -3.41 ± 1.41 | -3.50 ± 1.28 |
| Week 72 | -3.41 ± 1.42 | -3.61 ± 1.24 |
| Week 84 | -3.40 ± 1.45 | -3.70 ± 1.19 |
| Week 96 | -3.46 ± 1.43 | -3.59 ± 1.32 |
| Week 120 | -3.49 ± 1.45 | -3.72 ± 1.20 |
| Week 144 | -3.51 ± 1.41 | -3.79 ± 1.29 |
| Week 168 | -3.52 ± 1.45 | -3.66 ± 1.30 |
| Week 192 | -3.55 ± 1.43 | -3.61 ± 1.48 |
| Week 216 | -3.59 ± 1.43 | -3.71 ± 1.24 |
| Week 240 | -3.57 ± 1.44 | -3.90 ± 1.35 |
| Week 264 | -3.64 ± 1.39 | -3.92 ± 1.36 |
| Week 288 | -3.80 ± 1.38 | -4.38 ± 1.33 |
| Week 312 | -3.86 ± 1.34 | -5.62 ± 0.86 |
| Week 336 | -3.86 ± 1.34 | — |
| Week 360 | -3.93 ± 1.34 | — |
| Week 384 | -3.99 ± 1.36 | — |
| Week 408 | -3.85 ± 1.44 | — |
| Week 432 | -4.11 ± 1.35 | — |
| Week 456 | -4.01 ± 1.14 | — |
| Week 480 | -3.69 ± 1.47 | — |
| Week 504 | -3.76 ± 1.24 | — |
| Week 516 | -3.76 ± 2.32 | — |
HAQ-DI is a standardized questionnaire used to assess the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; hygiene; reach; grip and activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3, where 0= no difficulty in physical function; 1= some difficulty in physical function; 2= much difficulty in physical function; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty in physical function) to 3 (extreme difficulty in physical function), where higher scores indicate more difficulty while performing daily living activities. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
| units on a scale | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | -0.56 ± 0.63 | -0.58 ± 0.59 |
| Week 4 | -0.59 ± 0.62 | -0.57 ± 0.52 |
| Week 8 | -0.63 ± 0.63 | -0.63 ± 0.53 |
| Week 12 | -0.65 ± 0.64 | -0.65 ± 0.57 |
| Week 24 | -0.69 ± 0.65 | -0.63 ± 0.60 |
| Week 36 | -0.70 ± 0.66 | -0.67 ± 0.61 |
| Week 48 | -0.70 ± 0.66 | -0.63 ± 0.60 |
| Week 60 | -0.70 ± 0.67 | -0.67 ± 0.50 |
| Week 72 | -0.71 ± 0.66 | -0.67 ± 0.59 |
| Week 84 | -0.71 ± 0.68 | -0.68 ± 0.59 |
| Week 96 | -0.72 ± 0.67 | -0.69 ± 0.58 |
| Week 120 | -0.74 ± 0.69 | -0.67 ± 0.55 |
| Week 144 | -0.73 ± 0.70 | -0.64 ± 0.61 |
| Week 168 | -0.74 ± 0.70 | -0.61 ± 0.59 |
| Week 192 | -0.74 ± 0.71 | -0.65 ± 0.65 |
| Week 216 | -0.75 ± 0.71 | -0.62 ± 0.69 |
| Week 240 | -0.74 ± 0.72 | -0.61 ± 0.64 |
| Week 264 | -0.76 ± 0.71 | -0.54 ± 0.62 |
Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both joint erosions (JE) for 44 joints and joint space narrowing (JSN) for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study Baseline in 2 years X-ray data at Week 0 and 48 of LTS11210 were reported.
| score on scale | Sarilumab + DMARD: EFC11072 Part B |
|---|---|
| Change at Week 0 | 1.05 ± 4.61 |
| Change at Week 48 | 1.34 ± 5.31 |
Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 3 years X-ray data (participants with study duration of more than 48 weeks in LTS11210) at Week 48 and 96 of LTS11210 from Campaign 2 were reported.
| score on scale | Sarilumab + DMARD: EFC11072 Part B |
|---|---|
| Change at Week 48 | 1.60 ± 5.96 |
| Change at Week 96 | 2.14 ± 7.20 |
Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS: sum of the scores from both erosion score and joint space narrowing score and ranged from 0 (normal, no progression) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Here, Baseline refers to the Baseline of initial study (EFC11072 Part B). In this outcome measure, change from initial study (EFC11072 Part B) Baseline in 5 years X-ray data (participants with study duration of more than 96 weeks in LTS11210) at Week 96, 144 and 192 of LTS11210 from Campaign 3 were reported.
| score on scale | Sarilumab + DMARD: EFC11072 Part B |
|---|---|
| Change at Week 96 | 1.83 ± 7.76 |
| Change at Week 144 | 2.24 ± 8.43 |
| Change at Week 192 | 2.83 ± 9.42 |
Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 of LTS11210 from Campaign 1 X-ray data were reported.
| percentage of participants | Sarilumab + DMARD: EFC11072 Part B |
|---|---|
| Week 0 | 51.9 |
| Week 48 | 51.2 |
Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 48 and 96 of LTS11210 from Campaign 2 X-ray data (participants with study duration of more than 48 weeks in LTS11210) were reported.
| percentage of participants | Sarilumab + DMARD: EFC11072 Part B |
|---|---|
| Week 48 | 46.6 |
| Week 96 | 44.2 |
Radiographic no progression: defined as a change from Baseline in Van der Heijde mTSS \<= 0. Van der Heijde modified Sharp method is composite X-ray scoring system used to assess structural (joint) disease progression in RA. The method evaluates both JE for 44 joints and JSN for 42 joints in bilateral hand and foot joints. Total mTSS was sum of scores from both erosion score and joint space narrowing score, ranged from 0 (normal, no progression) to 448 (worst possible total score). Increase in total score represents progression of structural damage. In this outcome measure, percentage of participants with no radiographic progression at Week 96, 144 and 192 of LTS11210 from Campaign 3 X-ray data (participants with study duration more than 96 weeks in LTS11210) were reported.
| percentage of participants | Sarilumab + DMARD: EFC11072 Part B |
|---|---|
| Week 96 | 48.6 |
| Week 144 | 46.0 |
| Week 192 | 41.8 |
TJC is the sum of all tender joints based on examination of the 68 joints of the fingers, elbows, hips, knees, ankles, and toes. Total TJC ranged from 0 (best) to 68 (worst), where higher score = more severity. Change from Baseline in TJC was reported in the outcome measure. Here, Baseline refers to Baseline of initial study (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
| joints | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | -16.67 ± 14.05 | -19.86 ± 12.43 |
| Week 4 | -18.97 ± 13.81 | -20.13 ± 12.64 |
| Week 8 | -19.72 ± 13.61 | -20.09 ± 11.73 |
| Week 12 | -20.20 ± 13.89 | -20.05 ± 12.99 |
| Week 24 | -20.67 ± 14.09 | -21.19 ± 12.55 |
| Week 36 | -20.68 ± 14.39 | -20.60 ± 12.19 |
| Week 48 | -20.95 ± 14.04 | -20.27 ± 13.54 |
| Week 60 | -21.29 ± 14.06 | -20.95 ± 12.66 |
| Week 72 | -21.41 ± 13.98 | -21.67 ± 12.65 |
| Week 84 | -21.53 ± 14.17 | -21.36 ± 13.04 |
| Week 96 | -21.65 ± 14.08 | -20.89 ± 13.50 |
| Week 120 | -21.92 ± 14.20 | -20.18 ± 12.73 |
| Week 144 | -22.13 ± 14.01 | -22.52 ± 13.41 |
| Week 168 | -22.35 ± 14.26 | -22.42 ± 13.34 |
| Week 192 | -22.62 ± 14.20 | -21.83 ± 13.79 |
| Week 216 | -22.69 ± 14.28 | -22.33 ± 13.29 |
| Week 240 | -22.89 ± 14.47 | -23.07 ± 14.24 |
| Week 264 | -23.09 ± 14.08 | -23.66 ± 15.02 |
| Week 288 | -22.59 ± 15.70 | -28.95 ± 14.79 |
| Week 312 | -23.47 ± 15.23 | -43.71 ± 12.12 |
| Week 336 | -23.37 ± 15.24 | — |
| Week 360 | -24.12 ± 14.89 | — |
| Week 384 | -24.73 ± 15.14 | — |
| Week 408 | -24.58 ± 14.97 | — |
| Week 432 | -25.33 ± 15.05 | — |
| Week 456 | -24.21 ± 14.37 | — |
| Week 480 | -21.23 ± 14.66 | — |
| Week 504 | -23.62 ± 13.63 | — |
| Week 516 | -24.00 ± 12.73 | — |
SJC is the sum of all swollen joints based on examination of the fingers, elbows, knees and toes. Total SJC ranged from 0 (best) to 66 (worst), where higher score = more severity. Change from Baseline in SJC was reported in the outcome measure. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
| joints | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | -11.36 ± 9.96 | -14.06 ± 9.65 |
| Week 4 | -12.81 ± 9.77 | -14.55 ± 9.19 |
| Week 8 | -13.43 ± 9.82 | -14.60 ± 9.30 |
| Week 12 | -13.77 ± 10.13 | -14.58 ± 9.31 |
| Week 24 | -14.28 ± 10.09 | -14.83 ± 9.64 |
| Week 36 | -14.37 ± 9.99 | -14.51 ± 9.70 |
| Week 48 | -14.53 ± 9.97 | -14.96 ± 9.22 |
| Week 60 | -14.75 ± 10.20 | -15.54 ± 9.49 |
| Week 72 | -14.76 ± 10.12 | -15.43 ± 9.67 |
| Week 84 | -14.84 ± 10.16 | -15.83 ± 9.50 |
| Week 96 | -15.03 ± 10.20 | -15.51 ± 10.24 |
| Week 120 | -15.09 ± 10.17 | -15.77 ± 9.95 |
| Week 144 | -15.18 ± 10.20 | -15.90 ± 8.57 |
| Week 168 | -15.16 ± 10.30 | -15.47 ± 8.91 |
| Week 192 | -15.26 ± 10.09 | -15.01 ± 9.17 |
| Week 216 | -15.25 ± 9.97 | -15.72 ± 8.65 |
| Week 240 | -15.43 ± 10.34 | -15.59 ± 9.08 |
| Week 264 | -15.50 ± 9.79 | -16.59 ± 9.53 |
| Week 288 | -14.67 ± 10.98 | -18.65 ± 8.90 |
| Week 312 | -15.38 ± 10.71 | -23.57 ± 9.83 |
| Week 336 | -15.51 ± 10.48 | — |
| Week 360 | -15.96 ± 10.76 | — |
| Week 384 | -16.42 ± 10.76 | — |
| Week 408 | -16.30 ± 11.47 | — |
| Week 432 | -16.62 ± 11.51 | — |
| Week 456 | -15.64 ± 10.65 | — |
| Week 480 | -15.43 ± 10.67 | — |
| Week 504 | -16.21 ± 10.94 | — |
| Week 516 | -13.00 ± 2.83 | — |
Physician global assessment of disease activity was measured on a 100 millimeters (mm) horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
| millimeters | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | -40.51 ± 23.82 | -46.38 ± 19.17 |
| Week 4 | -43.98 ± 22.03 | -47.94 ± 19.16 |
| Week 8 | -45.79 ± 22.06 | -49.27 ± 18.80 |
| Week 12 | -47.02 ± 22.03 | -50.20 ± 19.74 |
| Week 24 | -48.39 ± 21.94 | -50.82 ± 19.99 |
| Week 36 | -48.94 ± 21.72 | -51.12 ± 19.87 |
| Week 48 | -49.36 ± 21.68 | -50.58 ± 21.38 |
| Week 60 | -49.98 ± 21.62 | -51.40 ± 20.51 |
| Week 72 | -49.91 ± 21.72 | -52.90 ± 19.40 |
| Week 84 | -50.28 ± 21.42 | -55.84 ± 17.39 |
| Week 96 | -50.73 ± 21.62 | -54.14 ± 18.97 |
| Week 120 | -50.43 ± 21.39 | -54.33 ± 19.41 |
| Week 144 | -50.84 ± 21.13 | -55.73 ± 18.04 |
| Week 168 | -50.49 ± 21.65 | -53.21 ± 21.36 |
| Week 192 | -50.32 ± 22.00 | -52.22 ± 22.44 |
| Week 216 | -51.49 ± 21.57 | -54.67 ± 18.30 |
| Week 240 | -51.00 ± 21.57 | -55.16 ± 18.82 |
| Week 264 | -51.18 ± 21.24 | -55.27 ± 21.70 |
Participant global assessment of disease activity was measured on a 100 mm horizontal VAS, ranging from 0 (best disease activity) to 100 (worst disease activity), where lower score = less disease activity and higher score = more disease activity. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
| millimeters | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | -30.51 ± 26.78 | -32.30 ± 27.55 |
| Week 4 | -32.87 ± 25.60 | -33.63 ± 25.86 |
| Week 8 | -34.65 ± 26.25 | -34.25 ± 25.90 |
| Week 12 | -35.60 ± 26.77 | -34.24 ± 28.38 |
| Week 24 | -36.91 ± 26.50 | -36.12 ± 27.82 |
| Week 36 | -37.08 ± 27.18 | -37.13 ± 24.73 |
| Week 48 | -37.28 ± 26.93 | -35.98 ± 28.18 |
| Week 60 | -37.79 ± 27.38 | -37.82 ± 25.40 |
| Week 72 | -37.90 ± 27.26 | -37.95 ± 26.53 |
| Week 84 | -37.45 ± 27.82 | -40.52 ± 26.69 |
| Week 96 | -38.34 ± 27.34 | -41.46 ± 26.57 |
| Week 120 | -38.41 ± 27.43 | -41.67 ± 26.43 |
| Week 144 | -38.91 ± 27.52 | -38.52 ± 26.40 |
| Week 168 | -38.22 ± 28.26 | -37.27 ± 27.46 |
| Week 192 | -39.26 ± 28.16 | -37.79 ± 32.12 |
| Week 216 | -39.96 ± 27.72 | -38.72 ± 32.76 |
| Week 240 | -39.54 ± 27.79 | -41.64 ± 30.13 |
| Week 264 | -39.87 ± 27.31 | -37.84 ± 32.94 |
| Week 288 | -43.68 ± 25.55 | -48.00 ± 33.87 |
| Week 312 | -44.05 ± 26.40 | -65.71 ± 21.40 |
| Week 336 | -43.42 ± 26.95 | — |
| Week 360 | -44.56 ± 26.59 | — |
| Week 384 | -47.19 ± 26.25 | — |
| Week 408 | -44.97 ± 29.16 | — |
| Week 432 | -49.77 ± 25.95 | — |
| Week 456 | -50.40 ± 24.27 | — |
| Week 480 | -46.65 ± 29.66 | — |
| Week 504 | -48.89 ± 28.83 | — |
| Week 516 | -40.50 ± 36.06 | — |
Participants were requested to indicate their pain intensity due to their RA on a 100 mm horizontal VAS, ranging from 0 (no pain) to 100 (worst pain), where a higher score represented more pain due to RA. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, EFC10832, SFY13370 and EFC13752).
| millimeters | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| Week 0 | -31.08 ± 27.45 | -37.01 ± 28.73 |
| Week 4 | -34.04 ± 26.52 | -37.53 ± 27.28 |
| Week 8 | -35.79 ± 26.88 | -38.14 ± 27.16 |
| Week 12 | -36.46 ± 27.46 | -39.08 ± 26.79 |
| Week 24 | -37.87 ± 27.07 | -38.75 ± 28.12 |
| Week 36 | -37.60 ± 27.97 | -39.56 ± 25.72 |
| Week 48 | -38.07 ± 28.33 | -39.41 ± 30.12 |
| Week 60 | -38.46 ± 28.18 | -40.79 ± 26.20 |
| Week 72 | -38.00 ± 28.54 | -42.62 ± 27.33 |
| Week 84 | -38.37 ± 28.79 | -42.38 ± 28.69 |
| Week 96 | -38.62 ± 28.57 | -43.73 ± 27.59 |
| Week 120 | -39.29 ± 28.44 | -44.11 ± 25.69 |
| Week 144 | -39.19 ± 28.21 | -41.42 ± 27.31 |
| Week 168 | -39.47 ± 28.84 | -38.86 ± 29.46 |
| Week 192 | -40.17 ± 28.98 | -41.25 ± 30.44 |
| Week 216 | -40.25 ± 28.56 | -44.01 ± 30.27 |
| Week 240 | -40.28 ± 28.44 | -43.59 ± 29.22 |
| Week 264 | -41.02 ± 28.09 | -40.71 ± 29.79 |
SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; where 0= worst QoL to 100=best QoL. PCS total score ranged from 0 to 100 with higher scores indicating better physical health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).
| units on a scale | Sarilumab + DMARD: EFC11072, ACT11575 and EFC10832 |
|---|---|
| Week 0 | 7.95 ± 8.29 |
| Week 12 | 8.84 ± 8.45 |
| Week 24 | 9.25 ± 8.59 |
| Week 36 | 9.72 ± 8.85 |
| Week 48 | 9.43 ± 8.89 |
| Week 60 | 9.64 ± 8.53 |
| Week 72 | 9.62 ± 8.78 |
| Week 84 | 9.95 ± 8.97 |
| Week 96 | 9.90 ± 8.90 |
| Week 120 | 10.18 ± 9.12 |
| Week 144 | 10.15 ± 9.18 |
| Week 168 | 10.24 ± 9.24 |
| Week 192 | 10.34 ± 9.52 |
| Week 216 | 10.15 ± 9.45 |
| Week 240 | 10.38 ± 9.21 |
| Week 264 | 10.32 ± 9.38 |
SF-36 is a generic 36-item questionnaire consisting of 8 domains, measuring quality of life (QoL) covering 2 summary measures: PCS and MCS. PCS with 4 domains: physical functioning, role limitations due to physical problems, bodily pain, and general health; and MCS with 4 domains: vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored by summing the individual items, which are transformed into a score range from 0 to 100; 0= worst QoL to 100=best QoL. MCS total score ranged from 0 to 100 with higher scores indicating better physical and mental health. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).
| units on a scale | Sarilumab + DMARD: EFC11072, ACT11575 and EFC10832 |
|---|---|
| Week 0 | 6.43 ± 10.80 |
| Week 12 | 7.15 ± 11.03 |
| Week 24 | 7.43 ± 11.15 |
| Week 36 | 7.20 ± 11.31 |
| Week 48 | 7.48 ± 11.15 |
| Week 60 | 7.43 ± 11.21 |
| Week 72 | 7.25 ± 11.24 |
| Week 84 | 7.29 ± 11.20 |
| Week 96 | 7.47 ± 11.52 |
| Week 120 | 7.69 ± 11.62 |
| Week 144 | 7.22 ± 11.60 |
| Week 168 | 7.29 ± 11.52 |
| Week 192 | 7.10 ± 11.51 |
| Week 216 | 7.20 ± 11.91 |
| Week 240 | 7.23 ± 12.03 |
| Week 264 | 7.32 ± 12.08 |
The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0 to 4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. The sum of all responses resulted in the FACIT-Fatigue total score ranged from 0 to 52, where higher score = lower level of fatigue and indicates better QoL. A positive change from baseline score indicates an improvement. Here, Baseline refers to the Baseline of initial studies (EFC11072, ACT11575, and EFC10832).
| units on a scale | Sarilumab + DMARD: EFC11072, ACT11575 and EFC10832 |
|---|---|
| Week 0 | 9.20 ± 10.05 |
| Week 12 | 10.26 ± 10.10 |
| Week 24 | 10.94 ± 10.31 |
| Week 36 | 10.91 ± 10.67 |
| Week 48 | 10.86 ± 10.64 |
| Week 60 | 10.97 ± 10.50 |
| Week 72 | 10.84 ± 10.68 |
| Week 84 | 10.75 ± 10.88 |
| Week 96 | 11.09 ± 10.85 |
| Week 120 | 11.18 ± 10.74 |
| Week 144 | 11.14 ± 10.86 |
| Week 168 | 11.00 ± 11.27 |
| Week 192 | 10.80 ± 11.10 |
| Week 216 | 11.12 ± 11.25 |
| Week 240 | 11.15 ± 11.21 |
| Week 264 | 10.99 ± 11.19 |
Rheumatoid arthritis (RA), like other chronic illness, is associated with sleep disturbances and is linked to pain, mood, and disease activity. The effect of sarilumab on sleep was assessed on a on 100 mm horizontal VAS scale, ranging from 0 (sleep is not a problem) to 100 (sleep is a major problem), where higher score = more sleep disturbances. Here, Baseline refers to the Baseline of initial studies (EFC11072, and ACT11575).
| millimeters | Sarilumab + DMARD: EFC11072, and ACT11575 |
|---|---|
| Week 0 | -24.58 ± 30.96 |
| Week 12 | -26.11 ± 30.59 |
| Week 24 | -26.44 ± 30.94 |
| Week 36 | -27.37 ± 31.52 |
| Week 48 | -26.15 ± 31.37 |
| Week 60 | -26.98 ± 31.24 |
| Week 72 | -26.85 ± 32.16 |
| Week 84 | -25.81 ± 31.90 |
| Week 96 | -26.91 ± 31.63 |
| Week 120 | -27.63 ± 32.26 |
| Week 144 | -26.90 ± 31.54 |
| Week 168 | -27.33 ± 33.25 |
| Week 192 | -26.87 ± 32.03 |
| Week 216 | -28.58 ± 31.46 |
| Week 240 | -27.72 ± 33.07 |
| Week 264 | -27.71 ± 32.08 |
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers indicated greater impairment). The percent work time missed due to RA was a subscale and calculated as: 100\*Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as impairment percentage (range:0 to 100%) where higher numbers indicate greater impairment and less productivity. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).
| units on a scale | Sarilumab + DMARD: EFC11072, and ACT11575 |
|---|---|
| Week 0 | -10.82 ± 30.64 |
| Week 12 | -8.62 ± 28.67 |
| Week 24 | -11.92 ± 29.33 |
| Week 36 | -9.62 ± 30.08 |
| Week 48 | -11.39 ± 29.92 |
| Week 60 | -10.03 ± 25.74 |
| Week 72 | -9.10 ± 28.14 |
| Week 84 | -8.20 ± 27.06 |
| Week 96 | -11.32 ± 30.28 |
| Week 120 | -8.62 ± 32.95 |
| Week 144 | -9.01 ± 30.16 |
| Week 168 | -10.38 ± 31.48 |
| Week 192 | -8.99 ± 29.24 |
| Week 216 | -11.17 ± 29.35 |
| Week 240 | -8.57 ± 26.11 |
| Week 264 | -13.40 ± 30.57 |
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers = less productivity); Q6 = degree problem affected regular activities (0 to 10 scale, with higher numbers = greater impairment). Percentage impairment while working due to RA was subscale and calculated as: 10\*Q5 for those who were currently employed and actually worked in past 7 days. Subscale score=expressed as impairment percentage (range:0 to 100%), where higher numbers=greater impairment and less productivity. Here, Baseline refers to the Baseline of initial studies (EFC11072 and ACT11575).
| units on a scale | Sarilumab + DMARD: EFC11072, and ACT11575 |
|---|---|
| Week 0 | -21.65 ± 27.74 |
| Week 12 | -22.16 ± 26.53 |
| Week 24 | -23.45 ± 26.70 |
| Week 36 | -27.01 ± 27.11 |
| Week 48 | -24.76 ± 26.05 |
| Week 60 | -25.17 ± 25.12 |
| Week 72 | -24.33 ± 27.57 |
| Week 84 | -24.02 ± 27.09 |
| Week 96 | -26.42 ± 27.11 |
| Week 120 | -24.02 ± 27.63 |
| Week 144 | -24.67 ± 28.20 |
| Week 168 | -24.25 ± 28.46 |
| Week 192 | -25.24 ± 26.60 |
| Week 216 | -24.56 ± 27.28 |
| Week 240 | -24.39 ± 26.48 |
| Week 264 | -25.26 ± 27.40 |
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent overall work impairment due to RA was subscale and calculated as: 100\*Q2/(Q2+Q4)+100\*\[(1- Q2/(Q2+Q4))\*(Q5/10)\] for those who were currently employed . Subscale score = expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).
| units on a scale | Sarilumab + DMARD: EFC11072, and ACT11575 |
|---|---|
| Week 0 | -22.84 ± 30.73 |
| Week 12 | -23.13 ± 27.98 |
| Week 24 | -25.39 ± 28.84 |
| Week 36 | -28.13 ± 29.01 |
| Week 48 | -24.72 ± 29.38 |
| Week 60 | -26.44 ± 28.03 |
| Week 72 | -25.06 ± 29.84 |
| Week 84 | -23.62 ± 29.25 |
| Week 96 | -27.06 ± 30.60 |
| Week 120 | -24.15 ± 31.14 |
| Week 144 | -23.97 ± 32.05 |
| Week 168 | -24.59 ± 31.16 |
| Week 192 | -24.77 ± 29.63 |
| Week 216 | -24.54 ± 31.55 |
| Week 240 | -25.05 ± 29.26 |
| Week 264 | -27.10 ± 28.75 |
WPAI assesses work productivity and impairment. It is 6-item questionnaire used to assess degree to which RA affected work productivity and regular activities over past 7 days. Questions were: Q1 = currently employed; Q2 = hours missed due to RA; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree problem affected productivity while working (0 to 10 scale, with higher numbers indicated less productivity); Q6 = degree problem affected regular activities (0 10 scale, with higher numbers indicated greater impairment). Percent activity impairment due to RA was a subscale and calculated as: 10\*Q6 for all respondents. Subscale score=expressed as impairment percentage (range: 0 to 100%) where higher numbers indicate greater impairment. Here, Baseline refers to Baseline of initial studies (EFC11072 and ACT11575).
| units on a scale | Sarilumab + DMARD: EFC11072, and ACT11575 |
|---|---|
| Week 0 | -26.47 ± 29.30 |
| Week 12 | -28.02 ± 27.44 |
| Week 24 | -28.76 ± 27.62 |
| Week 36 | -29.71 ± 28.03 |
| Week 48 | -29.11 ± 28.28 |
| Week 60 | -29.81 ± 27.78 |
| Week 72 | -29.61 ± 29.02 |
| Week 84 | -30.28 ± 29.53 |
| Week 96 | -30.28 ± 28.32 |
| Week 120 | -30.42 ± 28.78 |
| Week 144 | -30.29 ± 28.90 |
| Week 168 | -30.64 ± 29.30 |
| Week 192 | -30.88 ± 29.36 |
| Week 216 | -30.36 ± 29.34 |
| Week 240 | -31.12 ± 29.63 |
| Week 264 | -31.97 ± 28.77 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with arthritis over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days missed in the last month due to arthritis by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).
| days | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -2.72 ± 6.38 |
| Week 12 | -3.66 ± 6.80 |
| Week 24 | -3.70 ± 6.85 |
| Week 36 | -3.73 ± 7.08 |
| Week 48 | -3.37 ± 7.18 |
| Week 60 | -3.55 ± 6.93 |
| Week 72 | -3.58 ± 7.07 |
| Week 84 | -3.11 ± 8.49 |
| Week 96 | -3.47 ± 7.57 |
| Week 120 | -3.54 ± 7.56 |
| Week 144 | -3.51 ± 6.84 |
| Week 168 | -3.73 ± 7.37 |
| Week 192 | -3.76 ± 7.21 |
| Week 216 | -3.51 ± 7.30 |
| Week 240 | -2.44 ± 6.70 |
| Week 264 | -2.86 ± 5.83 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from Baseline in number of work days with reduced productivity by \>= 50% in the last month by the participant was reported in the outcome measure. Here, Baseline refers to the Baseline of initial study (EFC10832).
| days | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -3.47 ± 7.64 |
| Week 12 | -4.93 ± 9.22 |
| Week 24 | -5.14 ± 7.67 |
| Week 36 | -5.47 ± 8.41 |
| Week 48 | -5.75 ± 8.14 |
| Week 60 | -5.16 ± 7.96 |
| Week 72 | -5.21 ± 7.74 |
| Week 84 | -4.40 ± 8.27 |
| Week 96 | -5.03 ± 6.91 |
| Week 120 | -4.63 ± 7.47 |
| Week 144 | -4.88 ± 7.53 |
| Week 168 | -4.67 ± 7.06 |
| Week 192 | -4.55 ± 7.25 |
| Week 216 | -4.42 ± 8.01 |
| Week 240 | -3.48 ± 7.56 |
| Week 264 | -3.97 ± 5.02 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).
| units on a scale | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -20.83 ± 30.51 |
| Week 12 | -27.95 ± 58.67 |
| Week 24 | -35.16 ± 31.45 |
| Week 36 | -37.48 ± 33.72 |
| Week 48 | -36.78 ± 31.58 |
| Week 60 | -40.35 ± 33.19 |
| Week 72 | -38.74 ± 32.73 |
| Week 84 | -39.62 ± 41.56 |
| Week 96 | -42.35 ± 32.19 |
| Week 120 | -37.84 ± 32.32 |
| Week 144 | -39.16 ± 32.28 |
| Week 168 | -38.11 ± 32.25 |
| Week 192 | -40.74 ± 34.96 |
| Week 216 | -39.19 ± 37.00 |
| Week 240 | -38.22 ± 38.24 |
| Week 264 | -39.24 ± 36.09 |
'The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with no household work/household work missed in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
| days | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -4.65 ± 9.44 |
| Week 12 | -6.17 ± 10.29 |
| Week 24 | -6.55 ± 9.92 |
| Week 36 | -6.65 ± 10.36 |
| Week 48 | -6.61 ± 10.57 |
| Week 60 | -6.84 ± 10.47 |
| Week 72 | -6.50 ± 10.72 |
| Week 84 | -6.56 ± 10.63 |
| Week 96 | -6.80 ± 10.32 |
| Week 120 | -6.81 ± 10.31 |
| Week 144 | -6.78 ± 10.67 |
| Week 168 | -7.04 ± 10.13 |
| Week 192 | -6.74 ± 10.51 |
| Week 216 | -6.78 ± 10.07 |
| Week 240 | -6.82 ± 10.02 |
| Week 264 | -6.95 ± 10.16 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
| days | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -4.08 ± 10.24 |
| Week 12 | -5.64 ± 10.93 |
| Week 24 | -6.01 ± 10.40 |
| Week 36 | -6.57 ± 10.29 |
| Week 48 | -7.06 ± 10.13 |
| Week 60 | -7.01 ± 10.30 |
| Week 72 | -6.70 ± 10.72 |
| Week 84 | -6.38 ± 10.79 |
| Week 96 | -7.05 ± 10.62 |
| Week 120 | -7.12 ± 10.37 |
| Week 144 | -6.58 ± 10.59 |
| Week 168 | -6.39 ± 10.28 |
| Week 192 | -6.01 ± 10.07 |
| Week 216 | -6.27 ± 10.30 |
| Week 240 | -6.31 ± 9.99 |
| Week 264 | -6.93 ± 9.43 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days missed of family/social/leisure activities in the last month by the participants was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
| days | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -2.94 ± 8.34 |
| Week 12 | -4.16 ± 8.38 |
| Week 24 | -4.50 ± 8.42 |
| Week 36 | -4.38 ± 8.88 |
| Week 48 | -4.44 ± 8.51 |
| Week 60 | -4.46 ± 8.31 |
| Week 72 | -4.20 ± 8.52 |
| Week 84 | -4.31 ± 8.30 |
| Week 96 | -4.38 ± 8.03 |
| Week 120 | -4.43 ± 8.01 |
| Week 144 | -4.17 ± 7.90 |
| Week 168 | -4.12 ± 8.16 |
| Week 192 | -4.23 ± 8.17 |
| Week 216 | -3.93 ± 8.03 |
| Week 240 | -4.03 ± 8.26 |
| Week 264 | -3.85 ± 7.65 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Change from baseline in number of days with outside help hired in the last month by the participant was reported. Here, Baseline refers to the Baseline of initial study (EFC10832).
| days | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -2.92 ± 10.14 |
| Week 12 | -4.24 ± 10.16 |
| Week 24 | -4.12 ± 10.47 |
| Week 36 | -4.28 ± 10.27 |
| Week 48 | -4.58 ± 10.12 |
| Week 60 | -4.21 ± 10.16 |
| Week 72 | -4.00 ± 9.52 |
| Week 84 | -3.81 ± 9.67 |
| Week 96 | -3.90 ± 10.11 |
| Week 120 | -3.90 ± 9.62 |
| Week 144 | -3.91 ± 9.73 |
| Week 168 | -4.14 ± 10.00 |
| Week 192 | -3.93 ± 10.14 |
| Week 216 | -4.19 ± 9.84 |
| Week 240 | -4.12 ± 10.43 |
| Week 264 | -4.05 ± 9.67 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire was interviewer-administered and was based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranged from 0 (no interference) to 10 (complete interference), where higher scores indicated more interference. Here, Baseline refers to the Baseline of initial study (EFC10832).
| units on a scale | Sarilumab + DMARD: EFC10832 |
|---|---|
| Week 0 | -23.24 ± 35.09 |
| Week 12 | -33.49 ± 35.76 |
| Week 24 | -36.94 ± 36.75 |
| Week 36 | -36.42 ± 39.35 |
| Week 48 | -37.45 ± 34.85 |
| Week 60 | -38.19 ± 34.55 |
| Week 72 | -36.48 ± 35.37 |
| Week 84 | -35.61 ± 39.69 |
| Week 96 | -36.81 ± 36.04 |
| Week 120 | -38.86 ± 35.22 |
| Week 144 | -36.23 ± 37.52 |
| Week 168 | -36.01 ± 39.84 |
| Week 192 | -35.80 ± 40.99 |
| Week 216 | -38.54 ± 39.81 |
| Week 240 | -40.08 ± 35.68 |
| Week 264 | -38.07 ± 42.39 |
AEs related to PFS-S included PTC-related AEs, device-related AEs, or AEs of injection site reaction. In this outcome measure, only PTC-related AEs, device-related AEs, or AEs of injection site reaction assessed during the sub-study were reported. TEAEs and SAEs reported during the sub-study were included in the main study data and no separate data collection and analysis was performed, as pre-planned in the protocol .
| Participants | PFS-S Sarilumab 150 mg q2w | PFS-S Sarilumab 200 mg q2w | PFS-S Sarilumab 200 to 150 mg q2w |
|---|---|---|---|
| PTC-related AEs | 0 | 0 | 0 |
| Device-related AEs | 0 | 0 | 0 |
| AEs of injection site reaction | 0 | 0 | 0 |
Collected over From first dose (i.e., Day 1 of study LTS11210) of IMP to last dose of IMP + 60 days (maximum duration: up to 523 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | 49/1,910 (2.6%) | 617/1,910 (32.3%) | 1,444/1,910 (75.6%) |
| Sarilumab Monotherapy | 3/111 (2.7%) | 27/111 (24.3%) | 82/111 (73.9%) |
| Event | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 52/1910 | 1/111 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 45/1910 | 2/111 |
| Atrial FibrillationCardiac disorders | 9/1910 | 2/111 |
| Clostridium Difficile InfectionInfections and infestations | 1/1910 | 2/111 |
| Haemorrhagic StrokeNervous system disorders | 0/1910 | 2/111 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 10/1910 | 2/111 |
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 32/1910 | 1/111 |
| CholelithiasisHepatobiliary disorders | 24/1910 | 0/111 |
| CellulitisInfections and infestations | 21/1910 | 0/111 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 0/1910 | 1/111 |
| Event | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 348/1910 | 18/111 |
| Accidental OverdoseInjury, poisoning and procedural complications | 330/1910 | 20/111 |
| Upper Respiratory Tract InfectionInfections and infestations | 303/1910 | 16/111 |
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 227/1910 | 16/111 |
| Urinary Tract InfectionInfections and infestations | 264/1910 | 14/111 |
| NasopharyngitisInfections and infestations | 249/1910 | 14/111 |
| HypertensionVascular disorders | 235/1910 | 4/111 |
| BronchitisInfections and infestations | 215/1910 | 12/111 |
| Alanine Aminotransferase IncreasedInvestigations | 201/1910 | 4/111 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 87/1910 | 9/111 |
Analysis was performed on all enrolled population.
| Age, Continuous(years) | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy | Total Title |
|---|---|---|---|
| Mean | 52.1 ± 11.8 | 52.9 ± 13.1 | 52.2 ± 11.9 |
| Sex: Female, Male(Participants) | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy | Total Title |
|---|---|---|---|
| Female | 1550 | 88 | 1638 |
| Male | 362 | 23 | 385 |
| Race/Ethnicity, Customized(Participants) | Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) | Sarilumab Monotherapy | Total Title |
|---|---|---|---|
| Caucasian/White | 1639 | 108 | 1747 |
| Black | 48 | 1 | 49 |
| Asian/Oriental | 69 | 1 | 70 |
| Other | 156 | 1 | 157 |
Showing the first 100 of 335 sites across 40 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jun 2010 to primary completion in Dec 2020, 126 months.
Results were first posted in Jan 2022, 1 year after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 126 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab